AstraZeneca PLC ADR (AZN)

47.23
+0.07(+0.15%)
After Hours
47.23
0.00(0.00%)
- Real-time Data
  • Volume:
    15,996,354
  • Bid/Ask
    46.87/47.14
  • Day's Range
    46.48 - 47.95

AZN Overview

Prev. Close
47.23
Day's Range
46.48 - 47.95
Revenue
26.62B
Open
47.59
52 wk Range
36.15 - 64.94
EPS
1.22
Volume
15,996,354
Market Cap
124.87B
Dividend (Yield)
2.35 (4.65%)
Average Volume (3m)
12,679,692
P/E Ratio
38.75
Beta
0.56
1-Year Change
-2.82%
Shares Outstanding
1,312,698,568
Next Earnings Date
29 Apr 2021
What is your sentiment on AstraZeneca PLC ADR?
or
Market is currently closed. Voting is open during market hours.

AstraZeneca PLC ADR News

  • UK Stocks-Factors to watch on March 5
    • ByReuters-

    March 5 (Reuters) - Britain's FTSE 100 .FTSE index is seenopening open 58 points lower at 6,593 on Friday, according tofinancial bookmakers.* EMISSIONS: Britain still has not set...

  • UPDATE 1-UK Stocks-Factors to watch on March 4
    • ByReuters-

    (Adds futures, news items)March 4 (Reuters) - Britain's FTSE 100 .FTSE index is seenopening 80 points lower at 6,595 on Thursday, according tofinancial bookmakers, with futures...

  • UK Stocks-Factors to watch on March 4
    • ByReuters-

    March 4 (Reuters) - Britain's FTSE 100 .FTSE index is seenopening 80 points lower at 6,595 on Thursday, according tofinancial bookmakers.* CAR SALES: British new car registrations...

AstraZeneca PLC ADR Analysis

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesBuyNeutralSellStrong SellNeutral
Technical IndicatorsStrong BuyBuyStrong SellStrong SellStrong Sell
SummaryStrong BuyNeutralStrong SellStrong SellSell

AstraZeneca PLC ADR Company Profile

AstraZeneca PLC ADR Company Profile

Employees
70600

AstraZeneca PLC is a biopharmaceutical company. It focuses on discovery and development of products, which are then manufactured, marketed and sold. It focuses on three main therapy areas: Oncology, Cardiovascular, Renal & Metabolic (CVRM) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience. In CVRM, it is expanding its portfolio into the cardiovascular-renal area with roxadustat, as well as investing to explore the benefits of its SGLT2 and GLP-1 franchises in chronic kidney disease (CKD) and heart failure (HF). It has approximately 38 projects in Phase I, including 26 new molecular entities (NMEs), and 12 oncology combination projects. It has approximately 43 projects in Phase II, including 25 NMEs; six additional indications for projects that have reached phase II, and 12 oncology combination projects. It has approximately 22 projects in late-stage development, either in Phase III/pivotal Phase II studies or under regulatory review.

Read More
    Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
    Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.